Syphilis Immunoassay Diagnostics Market By Product Type (Analyzers, Kits and reagents), By Technology (CLIA, ELISA), By End User (Blood Banks, Diagnostic Labs, Hospitals): Global Opportunity Analysis and Industry Forecast, 2021-2031

Syphilis Immunoassay Diagnostics Market

Syphilis is a sexually transmitted infection caused by Treponema pallidum. The disease is mainly diagnosed through clinical findings and serologic testing. However, no single serologic test of syphilis is sufficient. Hence, the serologic diagnosis of syphilis requires the detection of two types of antibodies (nontreponemal antibodies and treponemal antibodies). 

The rise in socioeconomic factors such as sexually transmitted diseases, increase in awareness about syphilis immunoassay diagnostics, and surge in government expenditure on healthcare drives the growth of the Syphilis Immunoassay Diagnostics Market Size. Moreover, Syphilis Immunoassay Diagnostics Market Trends such as increase in rates of fatal syphilis infections, surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing further helps in the growth of the Syphilis Immunoassay Diagnostics Industry. However, a lack of knowledge among individuals in emerging economies is expected to hinder the growth of this market.

The global Syphilis Immunoassay Diagnostics Market Share is segmented based on product type, technology, end user, and region. On the basis of product type, the market is divided into analyzers and kits & reagents. Depending on technology, the market is classified into CLIA and ELISA. As per end user, the market is classified into blood banks, diagnostic labs, and hospitals. Region wise, the market is studied across North America, Europe, Asia-Pacific, and LAMEA.

On the basis of product type, the market is classified into analyzers and kits & reagents. The kits and reagents segment is projected to exhibit the largest Syphilis Immunoassay Diagnostics Market Share during the forecast period, owing to increase in the prevalence of syphilis among the population, surge in healthcare expenditure, and rise in adoption of syphilis diagnostic products for screening.

On the basis of technology, the market is classified into CLIA and ELISA. The CLIA segment is anticipated to have largest Syphilis Immunoassay Diagnostics Market Size, owing to upsurge in number of patients of sexually transmitted diseases, increase in the number of diagnosis procedures of syphilis, growth in Syphilis Immunoassay Diagnostics Industry and rise in number of research and development activities for syphilis testing. Moreover, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing helps in the growth of the market.

On the basis of end user, the market is classified into blood banks, diagnostic labs, and hospitals. The blood banks segment is anticipated to grow at the highest rate, owing to increase in the number of biotechnology companies and rise in research activities of cell therapy. Moreover, the rise in number of pharmaceutical companies contributes in the growth of the market.

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant during the Syphilis Immunoassay Diagnostics Market Forecast period, owing to the high prevalence rate of syphilis, increase in the number of market players, and surge in testing facilities in the region. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, owing to the presence of high populace countries such as India and China, which in turn increases the prevalence rate of sexually transmitted diseases and the increasing number of strategies and trends adopted by the market players.

KEY FINDINGS OF THE STUDY

By product type, the kits and reagents segment accounted for major share of the Syphilis Immunoassay Diagnostics Market Analysis in 2021.

By technology, the CLIA segment is anticipated to grow with the highest CAGR during the forecast period.

By end user, the blood banks segment is anticipated to grow with the highest CAGR during the forecast period.

By region, North America occupied major share of the syphilis immunoassay diagnostics market in 2021.

Overview

The global syphilis immunoassay diagnostics market was valued at $315.5 million in 2021, and is projected to reach $446.0 million by 2031, registering a CAGR of 3.5% from 2022 to 2031.

Syphilis is a chronic bacterial infection that can be transmitted through sexual contact. It is caused by a type of bacteria known as Treponema pallidum. The four stages of syphilis include primary, secondary, latent, and tertiary. The primary stage of syphilis occurs about 3 to 4 weeks after a person contracts the bacteria. Skin rashes and a sore throat may develop during the second stage of syphilis. The primary and secondary symptoms disappear, and there won’t be any noticeable symptoms at the latent stage of syphilis. The tertiary stage can cause blindness, loss of hearing, and mental health conditions. The diagnosis of this disease includes the collection of spinal fluid for the screening test of syphilis. Moreover, the blood test for syphilis tests for antibodies directed at the syphilis organism (Treponema pallidum). The available tests for syphilis include the microhemagglutination assay for T pallidum, the T pallidum particle agglutination, the T pallidum hemagglutination assay, the fluorescent treponemal antibody absorbed (FTA-ABS) test, and chemoluminescence immunoassays and enzyme immunoassays that detect Treponemal antibodies.

The growth of the syphilis immunoassay diagnostics market is driven by rising in socioeconomic factors such as sexually transmitted diseases and an increase in the proportion of sex under the influence of numerous drugs such as heroin, cocaine, methamphetamine, cannabis, benzodiazepines, and alcohol. Moreover, the increase in rates of fatal syphilis infections, the surge in testing facilities, the widespread use of technology in testing, and the availability of on-the-spot testing also help in the growth of the market. For instance, according to the data from World Health Organization (WHO), there were an estimated 374 million new infections with 1 of 4 STIs like chlamydia (129 million), gonorrhea (82 million), syphilis (7.1 million), and trichomoniasis (156 million) in 2020. However, a lack of knowledge among individuals in emerging economies is expected to hinder the growth of this market. Conversely, the high growth potential in untapped emerging economies is expected to create lucrative opportunities for the market.

The global syphilis immunoassay diagnostics market is segmented based on product type, technology, end-user, and region. As per product type, the market is divided into analyzers and kits & reagents. Depending on the technology, the market is bifurcated into CLIA and ELISA. According to end users, the market is classified into blood banks, diagnostic labs, and hospitals. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and the rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).

Key Benefits For Stakeholders

●This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the syphilis immunoassay diagnostics market analysis from 2021 to 2031 to identify the prevailing syphilis immunoassay diagnostics market opportunities.

●The market research is offered along with information related to key drivers, restraints, and opportunities.

●Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

●In-depth analysis of the syphilis immunoassay diagnostics market segmentation assists to determine the prevailing market opportunities.

●Major countries in each region are mapped according to their revenue contribution to the global market.

●Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

●The report includes the analysis of the regional as well as global syphilis immunoassay diagnostics market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

○ Shenzhen New Industries Biomedical Engineering Co. Lt

Scope of Syphilis Immunoassay Diagnostics Market Report

1.1.Report description

1.2.Key market segments

1.3.Key benefits to the stakeholders

1.4.Research Methodology

1.4.1.Secondary research

1.4.2.Primary research

1.4.3.Analyst tools and models

2.1.Key findings of the study

2.2.CXO Perspective

3.1.Market definition and scope

3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five forces analysis

3.4.Top player positioning

3.5.Market dynamics

3.5.1.Drivers

3.5.2.Restraints

3.5.3.Opportunities

3.6.COVID-19 Impact Analysis on the market

4.1 Overview

4.1.1 Market size and forecast

4.2 Analyzers

4.2.1 Key market trends, growth factors and opportunities

4.2.2 Market size and forecast, by region

4.2.3 Market share analysis by country

4.3 Kits and reagents

4.3.1 Key market trends, growth factors and opportunities

4.3.2 Market size and forecast, by region

4.3.3 Market share analysis by country

5.1 Overview

5.1.1 Market size and forecast

5.2 CLIA

5.2.1 Key market trends, growth factors and opportunities

5.2.2 Market size and forecast, by region

5.2.3 Market share analysis by country

5.3 ELISA

5.3.1 Key market trends, growth factors and opportunities

5.3.2 Market size and forecast, by region

5.3.3 Market share analysis by country

6.1 Overview

6.1.1 Market size and forecast

6.2 Blood Banks

6.2.1 Key market trends, growth factors and opportunities

6.2.2 Market size and forecast, by region

6.2.3 Market share analysis by country

6.3 Diagnostic Labs

6.3.1 Key market trends, growth factors and opportunities

6.3.2 Market size and forecast, by region

6.3.3 Market share analysis by country

6.4 Hospitals

6.4.1 Key market trends, growth factors and opportunities

6.4.2 Market size and forecast, by region

6.4.3 Market share analysis by country

7.1 Overview

7.1.1 Market size and forecast

7.2 North America

7.2.1 Key trends and opportunities

7.2.2 North America Market size and forecast, by Product Type

7.2.3 North America Market size and forecast, by Technology

7.2.4 North America Market size and forecast, by End User

7.2.5 North America Market size and forecast, by country

7.2.5.1 U.S.

7.2.5.1.1 Key market trends, growth factors and opportunities

7.2.5.1.2 Market size and forecast, by Product Type

7.2.5.1.3 Market size and forecast, by Technology

7.2.5.1.4 Market size and forecast, by End User

7.2.5.2 Canada

7.2.5.2.1 Key market trends, growth factors and opportunities

7.2.5.2.2 Market size and forecast, by Product Type

7.2.5.2.3 Market size and forecast, by Technology

7.2.5.2.4 Market size and forecast, by End User

7.2.5.3 Mexico

7.2.5.3.1 Key market trends, growth factors and opportunities

7.2.5.3.2 Market size and forecast, by Product Type

7.2.5.3.3 Market size and forecast, by Technology

7.2.5.3.4 Market size and forecast, by End User

7.3 Europe

7.3.1 Key trends and opportunities

7.3.2 Europe Market size and forecast, by Product Type

7.3.3 Europe Market size and forecast, by Technology

7.3.4 Europe Market size and forecast, by End User

7.3.5 Europe Market size and forecast, by country

7.3.5.1 Germany

7.3.5.1.1 Key market trends, growth factors and opportunities

7.3.5.1.2 Market size and forecast, by Product Type

7.3.5.1.3 Market size and forecast, by Technology

7.3.5.1.4 Market size and forecast, by End User

7.3.5.2 France

7.3.5.2.1 Key market trends, growth factors and opportunities

7.3.5.2.2 Market size and forecast, by Product Type

7.3.5.2.3 Market size and forecast, by Technology

7.3.5.2.4 Market size and forecast, by End User

7.3.5.3 UK

7.3.5.3.1 Key market trends, growth factors and opportunities

7.3.5.3.2 Market size and forecast, by Product Type

7.3.5.3.3 Market size and forecast, by Technology

7.3.5.3.4 Market size and forecast, by End User

7.3.5.4 Italy

7.3.5.4.1 Key market trends, growth factors and opportunities

7.3.5.4.2 Market size and forecast, by Product Type

7.3.5.4.3 Market size and forecast, by Technology

7.3.5.4.4 Market size and forecast, by End User

7.3.5.5 Spain

7.3.5.5.1 Key market trends, growth factors and opportunities

7.3.5.5.2 Market size and forecast, by Product Type

7.3.5.5.3 Market size and forecast, by Technology

7.3.5.5.4 Market size and forecast, by End User

7.3.5.6 Rest of Europe

7.3.5.6.1 Key market trends, growth factors and opportunities

7.3.5.6.2 Market size and forecast, by Product Type

7.3.5.6.3 Market size and forecast, by Technology

7.3.5.6.4 Market size and forecast, by End User

7.4 Asia-Pacific

7.4.1 Key trends and opportunities

7.4.2 Asia-Pacific Market size and forecast, by Product Type

7.4.3 Asia-Pacific Market size and forecast, by Technology

7.4.4 Asia-Pacific Market size and forecast, by End User

7.4.5 Asia-Pacific Market size and forecast, by country

7.4.5.1 Japan

7.4.5.1.1 Key market trends, growth factors and opportunities

7.4.5.1.2 Market size and forecast, by Product Type

7.4.5.1.3 Market size and forecast, by Technology

7.4.5.1.4 Market size and forecast, by End User

7.4.5.2 China

7.4.5.2.1 Key market trends, growth factors and opportunities

7.4.5.2.2 Market size and forecast, by Product Type

7.4.5.2.3 Market size and forecast, by Technology

7.4.5.2.4 Market size and forecast, by End User

7.4.5.3 Australia

7.4.5.3.1 Key market trends, growth factors and opportunities

7.4.5.3.2 Market size and forecast, by Product Type

7.4.5.3.3 Market size and forecast, by Technology

7.4.5.3.4 Market size and forecast, by End User

7.4.5.4 India

7.4.5.4.1 Key market trends, growth factors and opportunities

7.4.5.4.2 Market size and forecast, by Product Type

7.4.5.4.3 Market size and forecast, by Technology

7.4.5.4.4 Market size and forecast, by End User

7.4.5.5 South Korea

7.4.5.5.1 Key market trends, growth factors and opportunities

7.4.5.5.2 Market size and forecast, by Product Type

7.4.5.5.3 Market size and forecast, by Technology

7.4.5.5.4 Market size and forecast, by End User

7.4.5.6 Rest of Asia-Pacific

7.4.5.6.1 Key market trends, growth factors and opportunities

7.4.5.6.2 Market size and forecast, by Product Type

7.4.5.6.3 Market size and forecast, by Technology

7.4.5.6.4 Market size and forecast, by End User

7.5 LAMEA

7.5.1 Key trends and opportunities

7.5.2 LAMEA Market size and forecast, by Product Type

7.5.3 LAMEA Market size and forecast, by Technology

7.5.4 LAMEA Market size and forecast, by End User

7.5.5 LAMEA Market size and forecast, by country

7.5.5.1 Brazil

7.5.5.1.1 Key market trends, growth factors and opportunities

7.5.5.1.2 Market size and forecast, by Product Type

7.5.5.1.3 Market size and forecast, by Technology

7.5.5.1.4 Market size and forecast, by End User

7.5.5.2 Saudi Arabia

7.5.5.2.1 Key market trends, growth factors and opportunities

7.5.5.2.2 Market size and forecast, by Product Type

7.5.5.2.3 Market size and forecast, by Technology

7.5.5.2.4 Market size and forecast, by End User

7.5.5.3 South Africa

7.5.5.3.1 Key market trends, growth factors and opportunities

7.5.5.3.2 Market size and forecast, by Product Type

7.5.5.3.3 Market size and forecast, by Technology

7.5.5.3.4 Market size and forecast, by End User

7.5.5.4 Rest of LAMEA

7.5.5.4.1 Key market trends, growth factors and opportunities

7.5.5.4.2 Market size and forecast, by Product Type

7.5.5.4.3 Market size and forecast, by Technology

7.5.5.4.4 Market size and forecast, by End User

8.1. Introduction

8.2. Top winning strategies

8.3. Product Mapping of Top 10 Player

8.4. Competitive Dashboard

8.5. Competitive Heatmap

8.6. Key developments

9.1 BioRad Laboratories Inc

9.1.1 Company overview

9.1.2 Company snapshot

9.1.3 Operating business segments

9.1.4 Product portfolio

9.1.5 Business performance

9.1.6 Key strategic moves and developments

9.2 Danaher Corporation

9.2.1 Company overview

9.2.2 Company snapshot

9.2.3 Operating business segments

9.2.4 Product portfolio

9.2.5 Business performance

9.2.6 Key strategic moves and developments

9.3 BECTON DICKINSON & COMPANY

9.3.1 Company overview

9.3.2 Company snapshot

9.3.3 Operating business segments

9.3.4 Product portfolio

9.3.5 Business performance

9.3.6 Key strategic moves and developments

9.4 , F. Hoffmann-La Roche AG

9.4.1 Company overview

9.4.2 Company snapshot

9.4.3 Operating business segments

9.4.4 Product portfolio

9.4.5 Business performance

9.4.6 Key strategic moves and developments

9.5 Siemens Healthineers AG

9.5.1 Company overview

9.5.2 Company snapshot

9.5.3 Operating business segments

9.5.4 Product portfolio

9.5.5 Business performance

9.5.6 Key strategic moves and developments

9.6 Diasorin S.P.A

9.6.1 Company overview

9.6.2 Company snapshot

9.6.3 Operating business segments

9.6.4 Product portfolio

9.6.5 Business performance

9.6.6 Key strategic moves and developments

9.7 Abbott Laboratories

9.7.1 Company overview

9.7.2 Company snapshot

9.7.3 Operating business segments

9.7.4 Product portfolio

9.7.5 Business performance

9.7.6 Key strategic moves and developments

9.8 Fujirebio

9.8.1 Company overview

9.8.2 Company snapshot

9.8.3 Operating business segments

9.8.4 Product portfolio

9.8.5 Business performance

9.8.6 Key strategic moves and developments

9.9 , BioMerieux SA

9.9.1 Company overview

9.9.2 Company snapshot

9.9.3 Operating business segments

9.9.4 Product portfolio

9.9.5 Business performance

9.9.6 Key strategic moves and developments

9.10 Shenzhen New Industries Biomedical Engineering Co. Ltd

9.10.1 Company overview

9.10.2 Company snapshot

9.10.3 Operating business segments

9.10.4 Product portfolio

9.10.5 Business performance

9.10.6 Key strategic moves and development

LIST OF TABLES

TABLE 1. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 2. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR ANALYZERS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 3. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR ANALYZERS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 4. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 5. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR KITS AND REAGENTS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 6. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 7. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR CLIA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 8. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR CLIA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 9. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR ELISA, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 10. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR ELISA, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 11. GLOBAL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 12. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR BLOOD BANKS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 13. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR BLOOD BANKS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 14. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 15. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR DIAGNOSTIC LABS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 16. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 17. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 18. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)

TABLE 19. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 20. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 21. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 22. NORTH AMERICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 23. U.S. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 24. U.S. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 25. U.S. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 26. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 27. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 28. CANADA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 29. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 30. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 31. MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 32. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 33. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 34. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 35. EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 36. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 37. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 38. GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 39. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 40. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 41. FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 42. UK SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 43. UK SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 44. UK SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 45. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 46. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 47. ITALY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 48. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 49. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 50. SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 51. REST OF EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 52. REST OF EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 53. REST OF EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 54. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 55. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 56. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 57. ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 58. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 59. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 60. JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 61. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 62. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 63. CHINA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 64. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 65. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 66. AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 67. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 68. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 69. INDIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 70. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 71. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 72. SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 73. REST OF ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 74. REST OF ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 75. REST OF ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 76. LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 77. LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 78. LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 79. LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)

TABLE 80. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 81. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 82. BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 83. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 84. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 85. SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 86. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 87. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 88. SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 89. REST OF LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2031 (REVENUE, $MILLION)

TABLE 90. REST OF LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2031 (REVENUE, $MILLION)

TABLE 91. REST OF LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)

TABLE 92.BIORAD LABORATORIES INC: COMPANY SNAPSHOT

TABLE 93.BIORAD LABORATORIES INC: OPERATING SEGMENTS

TABLE 94.BIORAD LABORATORIES INC: PRODUCT PORTFOLIO

TABLE 95.BIORAD LABORATORIES INC: NET SALES

TABLE 96.BIORAD LABORATORIES INC: KEY STRATERGIES

TABLE 97.DANAHER CORPORATION: COMPANY SNAPSHOT

TABLE 98.DANAHER CORPORATION: OPERATING SEGMENTS

TABLE 99.DANAHER CORPORATION: PRODUCT PORTFOLIO

TABLE 100.DANAHER CORPORATION: NET SALES

TABLE 101.DANAHER CORPORATION: KEY STRATERGIES

TABLE 102.BECTON DICKINSON & COMPANY: COMPANY SNAPSHOT

TABLE 103.BECTON DICKINSON & COMPANY: OPERATING SEGMENTS

TABLE 104.BECTON DICKINSON & COMPANY: PRODUCT PORTFOLIO

TABLE 105.BECTON DICKINSON & COMPANY: NET SALES

TABLE 106.BECTON DICKINSON & COMPANY: KEY STRATERGIES

TABLE 107., F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT

TABLE 108., F. HOFFMANN-LA ROCHE AG: OPERATING SEGMENTS

TABLE 109., F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO

TABLE 110., F. HOFFMANN-LA ROCHE AG: NET SALES

TABLE 111., F. HOFFMANN-LA ROCHE AG: KEY STRATERGIES

TABLE 112.SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT

TABLE 113.SIEMENS HEALTHINEERS AG: OPERATING SEGMENTS

TABLE 114.SIEMENS HEALTHINEERS AG: PRODUCT PORTFOLIO

TABLE 115.SIEMENS HEALTHINEERS AG: NET SALES

TABLE 116.SIEMENS HEALTHINEERS AG: KEY STRATERGIES

TABLE 117.DIASORIN S.P.A: COMPANY SNAPSHOT

TABLE 118.DIASORIN S.P.A: OPERATING SEGMENTS

TABLE 119.DIASORIN S.P.A: PRODUCT PORTFOLIO

TABLE 120.DIASORIN S.P.A: NET SALES

TABLE 121.DIASORIN S.P.A: KEY STRATERGIES

TABLE 122.ABBOTT LABORATORIES: COMPANY SNAPSHOT

TABLE 123.ABBOTT LABORATORIES: OPERATING SEGMENTS

TABLE 124.ABBOTT LABORATORIES: PRODUCT PORTFOLIO

TABLE 125.ABBOTT LABORATORIES: NET SALES

TABLE 126.ABBOTT LABORATORIES: KEY STRATERGIES

TABLE 127.FUJIREBIO: COMPANY SNAPSHOT

TABLE 128.FUJIREBIO: OPERATING SEGMENTS

TABLE 129.FUJIREBIO: PRODUCT PORTFOLIO

TABLE 130.FUJIREBIO: NET SALES

TABLE 131.FUJIREBIO: KEY STRATERGIES

TABLE 132., BIOMERIEUX SA: COMPANY SNAPSHOT

TABLE 133., BIOMERIEUX SA: OPERATING SEGMENTS

TABLE 134., BIOMERIEUX SA: PRODUCT PORTFOLIO

TABLE 135., BIOMERIEUX SA: NET SALES

TABLE 136., BIOMERIEUX SA: KEY STRATERGIES

TABLE 137.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD: COMPANY SNAPSHOT

TABLE 138.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD: OPERATING SEGMENTS

TABLE 139.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD: PRODUCT PORTFOLIO

TABLE 140.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD: NET SALES

TABLE 141.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD: KEY STRATERGIES LIST OF FIGURES

FIGURE 1.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET SEGMENTATION

FIGURE 2.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031

FIGURE 3.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031

FIGURE 4. TOP INVESTMENT POCKETS, BY REGION

FIGURE 5.PORTER FIVE-1

FIGURE 6.PORTER FIVE-2

FIGURE 7.PORTER FIVE-3

FIGURE 8.PORTER FIVE-4

FIGURE 9.PORTER FIVE-5

FIGURE 10.TOP PLAYER POSITIONING

FIGURE 11.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES

FIGURE 12.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,BY PRODUCT TYPE,2021(%)

FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ANALYZERS SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 14.COMPARATIVE SHARE ANALYSIS OF KITS AND REAGENTS SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 15.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,BY TECHNOLOGY,2021(%)

FIGURE 16.COMPARATIVE SHARE ANALYSIS OF CLIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 17.COMPARATIVE SHARE ANALYSIS OF ELISA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 18.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,BY END USER,2021(%)

FIGURE 19.COMPARATIVE SHARE ANALYSIS OF BLOOD BANKS SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 20.COMPARATIVE SHARE ANALYSIS OF DIAGNOSTIC LABS SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITALS SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031(%)

FIGURE 22.SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET BY REGION,2021

FIGURE 23.U.S. SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 24.CANADA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 25.MEXICO SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 26.GERMANY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 27.FRANCE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 28.UK SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 29.ITALY SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 30.SPAIN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 31.REST OF EUROPE SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 32.JAPAN SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 33.CHINA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 34.AUSTRALIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 35.INDIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 36.SOUTH KOREA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 37.REST OF ASIA-PACIFIC SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 38.BRAZIL SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 39.SAUDI ARABIA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 40.SOUTH AFRICA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 41.REST OF LAMEA SYPHILIS IMMUNOASSAY DIAGNOSTICS MARKET,2021-2031($MILLION)

FIGURE 42. TOP WINNING STRATEGIES, BY YEAR

FIGURE 43. TOP WINNING STRATEGIES, BY DEVELOPMENT

FIGURE 44. TOP WINNING STRATEGIES, BY COMPANY

FIGURE 45.PRODUCT MAPPING OF TOP 10 PLAYERS

FIGURE 46.COMPETITIVE DASHBOARD

FIGURE 47.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS

FIGURE 48.BIORAD LABORATORIES INC.: NET SALES ($MILLION)

FIGURE 49.DANAHER CORPORATION.: NET SALES ($MILLION)

FIGURE 50.BECTON DICKINSON & COMPANY.: NET SALES ($MILLION)

FIGURE 51., F. HOFFMANN-LA ROCHE AG.: NET SALES ($MILLION)

FIGURE 52.SIEMENS HEALTHINEERS AG.: NET SALES ($MILLION)

FIGURE 53.DIASORIN S.P.A.: NET SALES ($MILLION)

FIGURE 54.ABBOTT LABORATORIES.: NET SALES ($MILLION)

FIGURE 55.FUJIREBIO.: NET SALES ($MILLION)

FIGURE 56., BIOMERIEUX SA.: NET SALES ($MILLION)

FIGURE 57.SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO. LTD.: NET SALES ($MILLION